CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

PET Imaging with Prostate-Specific Membrane Antigen for Prostate Cancer: Clinical Utility

Last updated: November 26, 2020
Project Number: RB1527-000
Product Line: Rapid Response
Research Type: Other Diagnostics
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the clinical utility of positron emission tomography (PET) imaging using prostate-specific membrane antigen (PSMA) labelled with gallium-68 (Ga-68) or fluorine-18 (F-18) in patients with suspected or confirmed metastatic or biochemically recurrent prostate cancer?

Key Message

Four systematic reviews (one with a meta-analysis), one randomized controlled trial, and 30 non-randomized studies were identified regarding the clinical utility of positron emission tomography imaging using prostate-specific membrane antigen labelled with gallium-68 or fluorine-18 in patients with suspected or confirmed metastatic or biochemically recurrent prostate cancer.